| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vomiting | 88 | 2024 | 137 | 13.680 |
Why?
|
| Antiemetics | 75 | 2023 | 95 | 12.870 |
Why?
|
| Nausea | 72 | 2024 | 111 | 11.560 |
Why?
|
| Antineoplastic Agents | 61 | 2023 | 663 | 7.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 40 | 2022 | 448 | 4.130 |
Why?
|
| Lung Neoplasms | 28 | 2023 | 674 | 3.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 20 | 2023 | 166 | 2.920 |
Why?
|
| Cisplatin | 37 | 2011 | 139 | 2.670 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 18 | 2023 | 23 | 2.510 |
Why?
|
| Isoquinolines | 7 | 2016 | 33 | 2.300 |
Why?
|
| Quinuclidines | 7 | 2016 | 21 | 2.300 |
Why?
|
| Morpholines | 14 | 2011 | 89 | 2.230 |
Why?
|
| Serotonin Antagonists | 21 | 2011 | 32 | 2.020 |
Why?
|
| Dexamethasone | 26 | 2016 | 205 | 2.010 |
Why?
|
| Pyridines | 5 | 2017 | 112 | 1.970 |
Why?
|
| Neoplasms | 34 | 2017 | 1364 | 1.890 |
Why?
|
| Ondansetron | 22 | 2011 | 33 | 1.480 |
Why?
|
| Drug Therapy, Combination | 17 | 2017 | 465 | 1.290 |
Why?
|
| Humans | 143 | 2024 | 63449 | 0.970 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2011 | 88 | 0.950 |
Why?
|
| Carcinoma, Small Cell | 5 | 2010 | 22 | 0.830 |
Why?
|
| Aged | 59 | 2018 | 14447 | 0.800 |
Why?
|
| Double-Blind Method | 24 | 2017 | 739 | 0.780 |
Why?
|
| Medical Oncology | 5 | 2023 | 66 | 0.760 |
Why?
|
| Middle Aged | 65 | 2018 | 17613 | 0.740 |
Why?
|
| Granisetron | 12 | 2003 | 13 | 0.720 |
Why?
|
| Male | 74 | 2020 | 29891 | 0.670 |
Why?
|
| Cannabinoids | 1 | 2020 | 41 | 0.650 |
Why?
|
| Female | 75 | 2023 | 32881 | 0.650 |
Why?
|
| Treatment Outcome | 28 | 2018 | 5680 | 0.650 |
Why?
|
| Cannabis | 1 | 2020 | 51 | 0.630 |
Why?
|
| Emetics | 6 | 2023 | 6 | 0.610 |
Why?
|
| Cyclophosphamide | 9 | 2023 | 82 | 0.570 |
Why?
|
| Aged, 80 and over | 32 | 2018 | 5462 | 0.570 |
Why?
|
| Drug Administration Schedule | 19 | 2011 | 298 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 13 | 2021 | 724 | 0.550 |
Why?
|
| Neoplasm Invasiveness | 3 | 2007 | 278 | 0.550 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2014 | 864 | 0.540 |
Why?
|
| Carboplatin | 8 | 2023 | 43 | 0.530 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2016 | 144 | 0.520 |
Why?
|
| Colorectal Neoplasms | 4 | 2011 | 276 | 0.510 |
Why?
|
| Adult | 48 | 2018 | 16824 | 0.500 |
Why?
|
| Spiro Compounds | 1 | 2016 | 11 | 0.500 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2022 | 188 | 0.500 |
Why?
|
| Taxoids | 4 | 2011 | 26 | 0.500 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2023 | 772 | 0.490 |
Why?
|
| Piperidines | 2 | 2011 | 63 | 0.480 |
Why?
|
| Salvage Therapy | 4 | 2012 | 75 | 0.470 |
Why?
|
| Neoplasm Staging | 12 | 2020 | 509 | 0.470 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 1644 | 0.440 |
Why?
|
| Clinical Trials as Topic | 10 | 2017 | 455 | 0.440 |
Why?
|
| Paclitaxel | 8 | 2022 | 99 | 0.400 |
Why?
|
| Guideline Adherence | 1 | 2015 | 305 | 0.400 |
Why?
|
| Radiation Oncology | 2 | 2024 | 51 | 0.400 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 117 | 0.400 |
Why?
|
| Infusions, Intravenous | 9 | 2011 | 173 | 0.390 |
Why?
|
| Serotonin 5-HT3 Receptor Antagonists | 6 | 2016 | 7 | 0.390 |
Why?
|
| Camptothecin | 2 | 2011 | 26 | 0.380 |
Why?
|
| Quinolizines | 6 | 1998 | 8 | 0.380 |
Why?
|
| Erlotinib Hydrochloride | 5 | 2018 | 19 | 0.380 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2015 | 44 | 0.380 |
Why?
|
| Vinblastine | 5 | 2011 | 18 | 0.380 |
Why?
|
| Mass Screening | 4 | 2015 | 691 | 0.370 |
Why?
|
| Deoxycytidine | 4 | 2018 | 42 | 0.370 |
Why?
|
| Indoles | 6 | 1998 | 110 | 0.360 |
Why?
|
| Piperazines | 1 | 2011 | 81 | 0.350 |
Why?
|
| Quinazolines | 3 | 2011 | 22 | 0.330 |
Why?
|
| Prognosis | 10 | 2021 | 1748 | 0.330 |
Why?
|
| Administration, Oral | 12 | 2014 | 369 | 0.320 |
Why?
|
| Radiotherapy | 7 | 2011 | 64 | 0.320 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2009 | 44 | 0.310 |
Why?
|
| Imidazoles | 5 | 1992 | 82 | 0.310 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 2 | 2006 | 4 | 0.300 |
Why?
|
| Catheterization, Peripheral | 1 | 2009 | 53 | 0.300 |
Why?
|
| Anemia | 2 | 2015 | 127 | 0.300 |
Why?
|
| Journalism, Medical | 1 | 2008 | 4 | 0.300 |
Why?
|
| Substance P | 3 | 2004 | 38 | 0.290 |
Why?
|
| Hemorrhage | 1 | 2009 | 267 | 0.280 |
Why?
|
| Publishing | 1 | 2008 | 93 | 0.270 |
Why?
|
| Drug Combinations | 3 | 2016 | 165 | 0.260 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 41 | 0.260 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 1094 | 0.250 |
Why?
|
| Pilot Projects | 6 | 2016 | 1008 | 0.250 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 321 | 0.240 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 175 | 0.240 |
Why?
|
| Palliative Care | 4 | 2020 | 230 | 0.240 |
Why?
|
| Prochlorperazine | 4 | 2000 | 5 | 0.240 |
Why?
|
| Time Factors | 6 | 2011 | 3768 | 0.230 |
Why?
|
| Maximum Tolerated Dose | 5 | 2007 | 40 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 259 | 0.230 |
Why?
|
| Metoclopramide | 6 | 1996 | 12 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2006 | 182 | 0.230 |
Why?
|
| Survival Rate | 8 | 2011 | 851 | 0.220 |
Why?
|
| Adenocarcinoma | 4 | 2015 | 348 | 0.220 |
Why?
|
| Evidence-Based Medicine | 4 | 2021 | 462 | 0.220 |
Why?
|
| Receptors, Neurokinin-1 | 2 | 2001 | 8 | 0.220 |
Why?
|
| Body Image | 1 | 2004 | 31 | 0.220 |
Why?
|
| Alopecia | 1 | 2004 | 27 | 0.220 |
Why?
|
| Injections, Intravenous | 10 | 2003 | 156 | 0.210 |
Why?
|
| Sclerosis | 1 | 2003 | 9 | 0.210 |
Why?
|
| Prospective Studies | 7 | 2011 | 3293 | 0.210 |
Why?
|
| Doxorubicin | 5 | 2011 | 99 | 0.210 |
Why?
|
| Erythropoietin | 1 | 2004 | 39 | 0.210 |
Why?
|
| Mediastinal Neoplasms | 1 | 2003 | 20 | 0.210 |
Why?
|
| Risk Factors | 7 | 2016 | 5354 | 0.210 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 61 | 0.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 68 | 0.200 |
Why?
|
| Neurotransmitter Agents | 1 | 2003 | 42 | 0.200 |
Why?
|
| Breast Neoplasms | 5 | 2015 | 1198 | 0.200 |
Why?
|
| Calcinosis | 1 | 2003 | 85 | 0.200 |
Why?
|
| Health Status | 1 | 2005 | 436 | 0.200 |
Why?
|
| Early Detection of Cancer | 2 | 2017 | 322 | 0.190 |
Why?
|
| Radiosurgery | 1 | 2023 | 62 | 0.190 |
Why?
|
| Anthracyclines | 2 | 2023 | 12 | 0.180 |
Why?
|
| Organoplatinum Compounds | 2 | 2011 | 21 | 0.180 |
Why?
|
| Drug Evaluation | 2 | 1998 | 19 | 0.180 |
Why?
|
| Societies, Medical | 3 | 2021 | 379 | 0.180 |
Why?
|
| Cross-Over Studies | 2 | 2020 | 161 | 0.180 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 507 | 0.170 |
Why?
|
| Incidence | 4 | 2014 | 1377 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2015 | 26 | 0.170 |
Why?
|
| Testicular Neoplasms | 3 | 1990 | 35 | 0.170 |
Why?
|
| Dronabinol | 1 | 2020 | 32 | 0.170 |
Why?
|
| Pemetrexed | 3 | 2022 | 11 | 0.160 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 105 | 0.160 |
Why?
|
| Acute Disease | 7 | 2005 | 671 | 0.160 |
Why?
|
| Survival Analysis | 4 | 2018 | 583 | 0.160 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 1990 | 10 | 0.150 |
Why?
|
| Benzene Derivatives | 1 | 1999 | 4 | 0.150 |
Why?
|
| Hospices | 2 | 2017 | 36 | 0.150 |
Why?
|
| United States | 7 | 2023 | 7846 | 0.150 |
Why?
|
| Risk | 2 | 2016 | 377 | 0.150 |
Why?
|
| Plant Extracts | 1 | 2020 | 172 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2001 | 352 | 0.150 |
Why?
|
| Drugs, Investigational | 1 | 1998 | 12 | 0.140 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 11 | 0.140 |
Why?
|
| Quinolines | 1 | 2018 | 45 | 0.140 |
Why?
|
| Placebos | 3 | 2006 | 72 | 0.140 |
Why?
|
| Drug Administration Routes | 4 | 2010 | 21 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 198 | 0.130 |
Why?
|
| Mutation | 3 | 2021 | 2612 | 0.130 |
Why?
|
| Serotonin | 3 | 2004 | 60 | 0.130 |
Why?
|
| Quality of Life | 1 | 2004 | 1229 | 0.130 |
Why?
|
| Critical Care | 1 | 2020 | 396 | 0.130 |
Why?
|
| Hospice Care | 1 | 2017 | 66 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2015 | 489 | 0.130 |
Why?
|
| Age Factors | 4 | 2006 | 1558 | 0.130 |
Why?
|
| Fluorouracil | 3 | 2011 | 66 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2016 | 42 | 0.120 |
Why?
|
| Esophageal Neoplasms | 3 | 2001 | 83 | 0.120 |
Why?
|
| Neutropenia | 5 | 2011 | 67 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 41 | 0.120 |
Why?
|
| Patient Selection | 2 | 2013 | 490 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 2000 | 14 | 0.110 |
Why?
|
| Leucovorin | 2 | 2011 | 9 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2017 | 268 | 0.110 |
Why?
|
| Glucocorticoids | 2 | 2010 | 188 | 0.110 |
Why?
|
| Consensus | 3 | 2023 | 208 | 0.110 |
Why?
|
| ErbB Receptors | 2 | 2018 | 114 | 0.110 |
Why?
|
| Diphtheria Toxin | 1 | 1993 | 6 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 1993 | 9 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2015 | 183 | 0.100 |
Why?
|
| Logistic Models | 2 | 2010 | 1276 | 0.100 |
Why?
|
| Interleukin-2 | 1 | 1993 | 167 | 0.100 |
Why?
|
| Combined Modality Therapy | 9 | 2001 | 373 | 0.100 |
Why?
|
| Smoking | 2 | 2014 | 866 | 0.100 |
Why?
|
| Remission Induction | 4 | 1997 | 148 | 0.090 |
Why?
|
| Algorithms | 1 | 1997 | 1003 | 0.090 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1991 | 21 | 0.090 |
Why?
|
| Area Under Curve | 1 | 2011 | 147 | 0.090 |
Why?
|
| Receptors, Serotonin | 3 | 1999 | 16 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 242 | 0.080 |
Why?
|
| Sex Factors | 2 | 2006 | 978 | 0.080 |
Why?
|
| SEER Program | 1 | 2010 | 74 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 89 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 2458 | 0.080 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 57 | 0.080 |
Why?
|
| Retroperitoneal Space | 1 | 2009 | 22 | 0.080 |
Why?
|
| Glutamates | 1 | 2009 | 13 | 0.080 |
Why?
|
| Flank Pain | 1 | 2009 | 8 | 0.080 |
Why?
|
| Stomach Neoplasms | 3 | 2000 | 79 | 0.080 |
Why?
|
| Guanine | 1 | 2009 | 23 | 0.080 |
Why?
|
| Patient Safety | 1 | 2012 | 242 | 0.080 |
Why?
|
| Adrenal Glands | 1 | 2009 | 33 | 0.080 |
Why?
|
| Probability | 2 | 2006 | 170 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 3 | 2004 | 341 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2009 | 134 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 1993 | 412 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2000 | 34 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 937 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 564 | 0.070 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 1987 | 4 | 0.070 |
Why?
|
| Topotecan | 1 | 2006 | 5 | 0.070 |
Why?
|
| Karnofsky Performance Status | 1 | 2006 | 12 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 264 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2006 | 240 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2015 | 6658 | 0.060 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2004 | 13 | 0.060 |
Why?
|
| Darbepoetin alfa | 1 | 2004 | 5 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 56 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 55 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2003 | 196 | 0.050 |
Why?
|
| Mitomycin | 3 | 1994 | 26 | 0.050 |
Why?
|
| Methylprednisolone | 2 | 2000 | 35 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2004 | 136 | 0.050 |
Why?
|
| Prodrugs | 1 | 2003 | 36 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 8 | 0.050 |
Why?
|
| Disease Progression | 1 | 2007 | 1172 | 0.050 |
Why?
|
| Lactams | 1 | 2022 | 18 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2000 | 35 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2022 | 31 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2022 | 32 | 0.050 |
Why?
|
| Body Weight | 1 | 2004 | 378 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2022 | 59 | 0.050 |
Why?
|
| Etoposide | 3 | 1993 | 34 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 78 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2022 | 137 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2000 | 345 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2001 | 102 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2018 | 2570 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 3 | 2005 | 149 | 0.040 |
Why?
|
| Anxiety | 1 | 2004 | 425 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2017 | 238 | 0.040 |
Why?
|
| Adolescent | 4 | 2005 | 6245 | 0.040 |
Why?
|
| Bleomycin | 3 | 1989 | 34 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 1999 | 3 | 0.040 |
Why?
|
| Models, Biological | 1 | 2004 | 1180 | 0.040 |
Why?
|
| Acetals | 1 | 1999 | 1 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 157 | 0.040 |
Why?
|
| American Medical Association | 1 | 2017 | 5 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 56 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 864 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2017 | 36 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 314 | 0.030 |
Why?
|
| Depression | 1 | 2004 | 894 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2011 | 568 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 130 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 1987 | 200 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2016 | 6 | 0.030 |
Why?
|
| Massachusetts | 2 | 2014 | 2075 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1996 | 36 | 0.030 |
Why?
|
| Platinum | 1 | 2015 | 20 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2016 | 56 | 0.030 |
Why?
|
| Mediastinoscopy | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hamartoma | 1 | 2015 | 12 | 0.030 |
Why?
|
| Granuloma | 1 | 2015 | 41 | 0.030 |
Why?
|
| Thoracotomy | 1 | 2015 | 46 | 0.030 |
Why?
|
| Headache | 1 | 1995 | 58 | 0.030 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2015 | 61 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 525 | 0.030 |
Why?
|
| Animals | 2 | 2008 | 20659 | 0.030 |
Why?
|
| Pleural Neoplasms | 1 | 1994 | 18 | 0.030 |
Why?
|
| Mesothelioma | 1 | 1994 | 28 | 0.030 |
Why?
|
| Chemoreceptor Cells | 1 | 1993 | 4 | 0.030 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1993 | 17 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 253 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 258 | 0.030 |
Why?
|
| Brain Stem | 1 | 1993 | 28 | 0.030 |
Why?
|
| Proteomics | 1 | 2015 | 283 | 0.030 |
Why?
|
| Radiology Information Systems | 1 | 2013 | 34 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2013 | 93 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 338 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2013 | 132 | 0.020 |
Why?
|
| Mucositis | 1 | 2011 | 7 | 0.020 |
Why?
|
| Orchiectomy | 2 | 1989 | 33 | 0.020 |
Why?
|
| Bridged Bicyclo Compounds | 1 | 1991 | 5 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1147 | 0.020 |
Why?
|
| Tropanes | 1 | 1991 | 6 | 0.020 |
Why?
|
| Indazoles | 1 | 1991 | 14 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 76 | 0.020 |
Why?
|
| Levamisole | 1 | 1991 | 8 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1120 | 0.020 |
Why?
|
| Benzamides | 1 | 1991 | 65 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 1991 | 49 | 0.020 |
Why?
|
| Research Design | 1 | 1994 | 574 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 422 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 1990 | 88 | 0.020 |
Why?
|
| Dysgerminoma | 1 | 1989 | 2 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 1989 | 15 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1654 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 475 | 0.020 |
Why?
|
| Mitomycins | 1 | 1988 | 6 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 199 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2681 | 0.020 |
Why?
|
| Medical History Taking | 1 | 1987 | 66 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2013 | 690 | 0.020 |
Why?
|
| Physical Examination | 1 | 1987 | 111 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1987 | 24 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2005 | 2079 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 125 | 0.020 |
Why?
|
| Epirubicin | 1 | 2005 | 4 | 0.010 |
Why?
|
| Pain Management | 1 | 1987 | 161 | 0.010 |
Why?
|
| Registries | 1 | 1989 | 888 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 331 | 0.010 |
Why?
|
| Social Support | 1 | 1987 | 371 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2004 | 17 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 168 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 753 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 896 | 0.010 |
Why?
|
| Esophagitis | 1 | 2001 | 9 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2000 | 84 | 0.010 |
Why?
|
| Radiography | 1 | 2000 | 550 | 0.010 |
Why?
|
| Demography | 1 | 1997 | 173 | 0.010 |
Why?
|
| Tamoxifen | 1 | 1996 | 41 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 1996 | 46 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 1999 | 433 | 0.010 |
Why?
|
| Asbestos | 1 | 1994 | 11 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1994 | 103 | 0.010 |
Why?
|
| Mammography | 1 | 1996 | 281 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 1994 | 218 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1991 | 144 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 1989 | 15 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1989 | 123 | 0.000 |
Why?
|
| Diagnostic Errors | 1 | 1989 | 101 | 0.000 |
Why?
|